Identification of Copy Number Alterations From Shallow Whole-Genome Sequencing in Multiple Myeloma [0.03%]
基于浅层全基因组测序的多发性骨髓瘤拷贝数变异识别
Jiali Li,Shaobing Gao,Zhenling Li et al.
Jiali Li et al.
Multiple myeloma (MM) is a malignant neoplasm of plasma cells leading to bone destruction and marrow failure. Prognosis and management of MM rely on cytogenetic determination of copy number alterations (CNAs). Nevertheless, karyotype analys...
Indolent T-Cell Lymphoma of the Gastrointestinal Tract Associated With Strongyloides Stercoralis Infection [0.03%]
肠道丝虫感染伴发的惰性T细胞淋巴瘤
Yue Zhao,Philip Petersen,Imran Siddiqi et al.
Yue Zhao et al.
Clinical and Prognostic Impact of Allelic Status in EZH2-Mutated Myeloid Neoplasms [0.03%]
EZH2突变髓系肿瘤的等位基因状态的临床和预后影响
Muhamad Oum,Ahmad Nanaa,Yazan Jabban et al.
Muhamad Oum et al.
The French Experience of Pharmacists and CAR T-Cells: A Study of the French Society of Oncology Pharmacy (SFPO) [0.03%]
法国药剂师的CAR-T细胞治疗经验：一项法国肿瘤学药房协会（SFPO）的研究
Vérane Schwiertz,Romain de Jorna,Adeline Quintard et al.
Vérane Schwiertz et al.
The aim of this study was to describe the initial 3-year experience in vein-to-vein time for axi-cel therapy and the role of pharmacists in the first recruiting French centers. Retrospective observational data were collected for vein-to-vei...
Observational Study
Hematological oncology. 2025 Nov;43(6):e70144. DOI:10.1002/hon.70144 2025
Thioguanine Therapy in Essential Thrombocytosis and Polycythemia Vera [0.03%]
硫鸟嘌呤治疗原发性血小板增多症和真性红细胞增多症
J Janssen,H J Boiten,H C T van Zaanen
J Janssen
Randomized Phase II Study of Brentuximab-Vedotin With High-Dose Chemotherapy in CD30 Positive Lymphoma [0.03%]
Brentuximab-Vedotin联合大剂量化疗治疗CD30阳性淋巴瘤的Ⅱ期随机临床研究
Christian Rausch,Ulrike Bacher,Manuela Rabaglio et al.
Christian Rausch et al.
Patients with Hodgkin lymphoma (HL) or peripheral T-cell lymphoma (PTCL) who relapse after high-dose chemotherapy (HDCT) have a dismal prognosis. Brentuximab-vedotin (BV) is a CD30-targeting antibody-drug-conjugate (ADC) used in first-line-...
Clinical Trial
Hematological oncology. 2025 Nov;43(6):e70143. DOI:10.1002/hon.70143 2025
A Multicenter Real-World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30-Positive Adult T-Cell Leukemia-Lymphoma [0.03%]
贝林妥欧单抗、环磷酰胺、多柔比星和泼尼松治疗成人T细胞白血病/淋巴瘤的疗效及安全性：真实世界回顾性研究
Masahito Tokunaga,Junya Makiyama,Motoaki Shiratsuchi et al.
Masahito Tokunaga et al.
Adult T-cell leukemia-lymphoma (ATL) is a rare, aggressive malignancy prevalent in Japan, the Caribbean, and Central/South America. This multicenter retrospective study evaluated the effectiveness and safety of brentuximab vedotin with cycl...
Multicenter Study
Hematological oncology. 2025 Nov;43(6):e70141. DOI:10.1002/hon.70141 2025
Long-Term Real-World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results [0.03%]
MATRix方案治疗原发中枢神经系统淋巴瘤患者的长期预后与IELSG32试验结果相似
Prokop Vodicka,Andrea Janikova,David Belada et al.
Prokop Vodicka et al.
Primary central nervous system lymphomas (PCNSL) are rare malignancies with poor survival outcomes. The IELSG32 trial demonstrated efficacy of MATRix chemoimmunotherapy followed by autologous stem cell transplantation (auto-SCT) in PCNSL pa...
Five-Year Follow-Up of Patients With Relapsed and Refractory Classic Hodgkin Lymphoma Treated With Low-Dose Nivolumab (40 mg): A Matched Cohort Study With Standard-Dose Therapy [0.03%]
利尤单抗低剂量（40毫克）治疗复发和难治性经典霍奇金淋巴瘤的5年随访：与标准剂量治疗队列相匹配的研究
Liudmila Fedorova,Kirill Lepik,Polina Kotselyabina et al.
Liudmila Fedorova et al.
The use of low-dose PD-1 inhibitors may offer a promising treatment strategy for patients with refractory Hodgkin lymphoma. This approach has the potential to mitigate the financial toxicity commonly associated with immune checkpoint inhibi...
Tissue-Equivalents of Lymphoid Clonal Hematopoiesis of Indeterminate Potential (L-CHIP) and Germline-Derived Lymphoproliferations: Possible Caveats for Hematopathologists [0.03%]
淋巴克隆不确定潜能的淋巴组织等同物和由胚系衍生的淋巴增殖性病变：血液病理学家应注意的问题
Magdalena M Brune,Ivana Bratic Hench,Stefan Dirnhofer et al.
Magdalena M Brune et al.
Clonal hematopoiesis of indeterminate potential (CHIP) is a predisposing condition to lymphoma development. CHIP carrying mutations that are recurrently found in lymphomas are designated as L-CHIP. We presume that bone marrow-derived L-CHIP...